Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
Invivyd (Nasdaq: IVVD) has announced a strategic partnership with professional football coach Jim Harbaugh to raise awareness about the ongoing impact of COVID-19. The initiative focuses on highlighting that COVID-19 remains a significant health concern, causing approximately one American death every 9 minutes, with about 59,000 deaths and 665,000 hospitalizations in 2024, despite widespread vaccination.
The partnership aims to educate the public, especially immunocompromised individuals such as cancer patients and organ transplant recipients, about COVID-19's short and potential long-term risks. Recent data shows increasing ICU admission rates for COVID-19 hospitalizations, and research suggests the long-term health and economic burden may exceed several other chronic diseases.
Through live and social media initiatives, Coach Harbaugh will help promote awareness and encourage people to learn more about available options beyond vaccines at www.expandtheiroptions.com. The campaign emphasizes that while COVID-19 is common, it should not be dismissed as merely a cold.
Invivyd (Nasdaq: IVVD) ha annunciato una partnership strategica con l'allenatore di football professionista Jim Harbaugh per sensibilizzare l'opinione pubblica sull'impatto duraturo del COVID-19. L'iniziativa si concentra sull'evidenziare che il COVID-19 rimane una significativa preoccupazione per la salute, causando circa un decesso americano ogni 9 minuti, con circa 59.000 decessi e 665.000 ricoveri nel 2024, nonostante la vaccinazione diffusa.
La partnership ha l'obiettivo di educare il pubblico, in particolare le persone immunocompromesse come i pazienti oncologici e i riceventi di trapianti d'organo, sui rischi a breve e potenzialmente a lungo termine del COVID-19. Dati recenti mostrano un aumento dei tassi di ricovero in terapia intensiva per COVID-19 e la ricerca suggerisce che il carico sanitario ed economico a lungo termine potrebbe superare diverse altre malattie croniche.
Attraverso iniziative di social media e eventi dal vivo, l'allenatore Harbaugh contribuirà a promuovere la consapevolezza e incoraggiare le persone a scoprire opzioni disponibili oltre ai vaccini su www.expandtheiroptions.com. La campagna sottolinea che, sebbene il COVID-19 sia comune, non dovrebbe essere considerato semplicemente un raffreddore.
Invivyd (Nasdaq: IVVD) ha anunciado una asociación estratégica con el entrenador de fútbol profesional Jim Harbaugh para aumentar la conciencia sobre el impacto continuo de COVID-19. La iniciativa se centra en resaltar que COVID-19 sigue siendo una preocupación significativa para la salud, causando aproximadamente una muerte estadounidense cada 9 minutos, con alrededor de 59,000 muertes y 665,000 hospitalizaciones en 2024, a pesar de la vacunación generalizada.
La asociación tiene como objetivo educar al público, especialmente a las personas inmunocomprometidas como los pacientes con cáncer y los receptores de trasplantes de órganos, sobre los riesgos a corto y potencialmente a largo plazo del COVID-19. Datos recientes muestran un aumento en las tasas de admisiones a la UCI por hospitalizaciones por COVID-19, y la investigación sugiere que la carga de salud y económica a largo plazo puede superar varias otras enfermedades crónicas.
A través de iniciativas en vivo y en redes sociales, el entrenador Harbaugh ayudará a promover la conciencia y animará a la gente a aprender más sobre las opciones disponibles más allá de las vacunas en www.expandtheiroptions.com. La campaña enfatiza que, aunque COVID-19 es común, no debe ser menospreciado como si fuera simplemente un resfriado.
Invivyd (Nasdaq: IVVD)는 코로나19의 지속적인 영향을 알리기 위해 프로 축구 코치 Jim Harbaugh와 전략적 파트너십을 맺었다고 발표했다. 이 이니셔티브는 COVID-19가 여전히 중요한 건강 문제임을 강조하며, 약 9분마다 미국에서 한 명이 사망하고, 2024년에는 약 59,000명이 사망하고 665,000명이 입원할 것이라고 언급했다. 이는 광범위한 백신 접종에도 불구하고 발생하는 일이다.
이번 파트너십은 면역이 저하된 암 환자 및 장기 이식 수혜자와 같은 사람들이 COVID-19의 단기적 및 잠재적 장기적 위험에 대해 교육받도록 하는 것을 목표로 한다. 최근 데이터에 따르면 COVID-19로 인한 입원 환자가 증가하고 있으며, 연구에 따르면 장기적인 건강 및 경제적 부담이 여러 만성 질환을 초과할 수 있다고 한다.
Harbaugh 코치는 라이브 및 소셜 미디어 이니셔티브를 통해 인식을 높이고 www.expandtheiroptions.com에서 백신 이상의 가능한 옵션에 대해 더 많은 정보를 찾도록 사람들을 격려할 것이다. 캠페인은 COVID-19가 흔하지만 단순한 감기로 치부되어서는 안 된다고 강조한다.
Invivyd (Nasdaq: IVVD) a annoncé un partenariat stratégique avec l'entraîneur de football professionnel Jim Harbaugh pour sensibiliser le public sur l'impact continu de la COVID-19. L'initiative se concentre sur le fait que la COVID-19 reste un problème de santé significatif, causant environ un décès américain toutes les 9 minutes, avec environ 59 000 décès et 665 000 hospitalisations en 2024, malgré la vaccination généralisée.
Le partenariat vise à éduquer le public, en particulier les individus immunodéprimés tels que les patients atteints de cancer et les receveurs de greffes d'organes, sur les risques à court et potentiellement à long terme liés à la COVID-19. Des données récentes montrent une augmentation des taux d'admission en soins intensifs pour hospitalisations dues à la COVID-19, et des recherches suggèrent que le fardeau sanitaire et économique à long terme pourrait dépasser plusieurs autres maladies chroniques.
Grâce à des initiatives en direct et sur les réseaux sociaux, l'entraîneur Harbaugh contribuera à promouvoir la sensibilisation et à encourager les gens à en savoir plus sur les options disponibles au-delà des vaccins sur www.expandtheiroptions.com. La campagne souligne que, bien que la COVID-19 soit courante, elle ne doit pas être considérée comme simplement un rhume.
Invivyd (Nasdaq: IVVD) hat eine strategische Partnerschaft mit dem professionellen Fußballtrainer Jim Harbaugh angekündigt, um das Bewusstsein für die anhaltenden Auswirkungen von COVID-19 zu schärfen. Die Initiative konzentriert sich darauf, dass COVID-19 ein bedeutendes Gesundheitsproblem bleibt, das etwa einen amerikanischen Tod alle 9 Minuten verursacht, mit rund 59.000 Todesfällen und 665.000 Krankenhauseinweisungen im Jahr 2024, trotz weit verbreiteter Impfungen.
Die Partnerschaft zielt darauf ab, die Öffentlichkeit, insbesondere immungeschwächte Personen wie Krebspatienten und Organtransplantierte, über die kurzfristigen und potenziellen langfristigen Risiken von COVID-19 aufzuklären. Aktuelle Daten zeigen eine steigende Anzahl von Intensivaufnahmen aufgrund von COVID-19 und Forschungsergebnisse deuten darauf hin, dass die langfristige Gesundheits- und Wirtschaftslast mehrere andere chronische Erkrankungen übersteigen könnte.
Durch Live- und Social-Media-Initiativen wird Coach Harbaugh dazu beitragen, das Bewusstsein zu fördern und die Menschen zu ermutigen, mehr über verfügbare Optionen über Impfstoffe hinweg auf www.expandtheiroptions.com zu erfahren. Die Kampagne betont, dass COVID-19, obwohl es häufig vorkommt, nicht einfach als Erkältung abgetan werden sollte.
- None.
- None.
- Teaming up to raise awareness of the continuing toll of COVID-19 in America, an ongoing mass disabling event causing an American death approximately every 9 minutes with over 59,000 deaths and 665,000 hospitalizations in 2024, as well as a lifetime of unknown impact, despite widespread vaccination
- In life as in football, Coach Harbaugh believes in options, including for those who are immunocompromised and may continue to live in fear of COVID-19, such as people who have cancer, had an organ transplant, or are on certain medications
- Proud to partner with a company driven to provide options for COVID-19, Coach Harbaugh encourages Americans, especially the immunocompromised, to learn more about the short and potential long-term impacts of COVID-19 and to learn more about their options at www.expandtheiroptions.com
WALTHAM, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced a strategic partnership with renowned professional football coach Jim Harbaugh to raise awareness about the ongoing short and potential long-term risks of COVID-19 to the broad population and especially people who are immunocompromised, and encourage people to learn more about their potential options. This collaboration will highlight Coach Harbaugh in live and social media initiatives.
Even nearly five years after the start of the pandemic, COVID-19 is causing an American death approximately every 9 minutes,1 and, in 2024, caused approximately 59,000 deaths,2 665,000 hospitalizations,2 and growing burden of Long COVID over time, despite broadly available and utilized vaccine boosts and small molecule therapy. In addition, the percentage of COVID-19 associated hospitalizations with intensive care unit (ICU) admissions is once again on the rise.3 A recent article published in the Journal of Infectious Diseases4 discusses how the current health and economic burden of the long-term impacts of COVID-19 may already exceed several other chronic diseases and will persist as COVID-19 cases continue to rise. This could be a significant drain not only on patients, but also on businesses, third party payers, healthcare systems, and all of society.
“As a long-time coach, I want players on the field, fans in the stands, and friends and family gathering to enjoy the game. But, COVID-19 has and continues to sideline many people,” said Coach Harbaugh. “While COVID-19 may seem like old news to some, many Americans continue to get sick, are hospitalized, and are dying from COVID-19, despite many of us having been vaccinated. The extent of damage to our bodies in the long-term is still unknown. The good news is for many there are options other than vaccines and people are encouraged to visit www.expandtheiroptions.com to learn more.”
“We are thrilled to have Coach Harbaugh on our team as we work to educate healthcare providers as well as the millions of immunocompromised people we serve about the continued prevalence and significant risks of COVID-19, which is common, but not a cold,” noted Julie Green, Invivyd’s Chief Human Resources Officer and Head of Communications. “We are grateful to Coach Harbaugh for his passion to raise awareness about the ongoing prevalence and impact of COVID-19 and his determination for people to seek options that may help them find ways to safely enjoy activities they love, like watching the big game with family and friends.”
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
1 “Trends in United States COVID-19 Deaths, Emergency Department (ED) Visits, and Test Positivity by Geographic Area”. COVID Data Tracker. Center for Disease Control and Prevention (CDC). https://covid.cdc.gov/covid-data-tracker/#trends_weeklydeaths_select_00. Accessed January 16, 2025.
2 From October 7, 2023, through September 28, 2024, the 2023-2024 respiratory season; hospitalizations calculated by Invivyd based on 334.9 million U.S. Census Bureau estimate of U.S. population size. Calculations based on cumulative rate for each disease state taken from the September 28, 2024 data point.
2 “Respiratory Virus Hospitalization Surveillance Network (RESP-NET)”. Center for Disease Control and Prevention (CDC). https://www.cdc.gov/resp-net/dashboard/?CDC. Accessed January 16, 2025.
2 “COVID-NET Laboratory-confirmed COVID-19 hospitalizations”. COVID Data Tracker. Center for Disease Control and Prevention (CDC). https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalization-network. Accessed January 16, 2025.
3 Hospitalization data based on calculations completed by Invivyd. Hospitalizations calculated based on 334.9 million US Census Bureau estimate of US population size. Data range from October 7, 2023, through September 28, 2024, the 2023-2024 respiratory season. ICU, intensive care unit. Reference: “COVID-19 Update for the United States”. COVID Data Tracker. Center for Disease Control and Prevention (CDC). https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalization-network. Accessed January 16, 2025.
4 Bartsch, Sarah M, et al. “The Current and Future Burden of Long COVID in the United States (U.S.)”. The Journal of Infectious Diseases. January 22, 2025. https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaf030/7972782?login=false. Accessed February 4, 2025.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "could," "expects," "estimates," "intends," "potential," "predicts," "projects," and "future" or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the company's expectations regarding its strategic partnership with Jim Harbaugh; the company’s efforts to provide options for COVID-19; expectations regarding the future COVID-19 landscape and the potential impacts of COVID-19; the company's devotion to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; the potential of Invivyd’s proprietary technology and its pipeline of innovative antibody candidates; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company's forward-looking statements and you should not place undue reliance on the company's forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: whether the anticipated benefits of the company’s strategic partnership with Jim Harbaugh are realized; the timing, progress and results of the company's discovery, preclinical and clinical development activities; the risk that results of nonclinical studies or clinical trials may not be predictive of future results; unexpected safety or efficacy data observed during preclinical studies or clinical trials; whether the company's product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways; changes in the regulatory environment; how long the EUA granted by the U.S. FDA for a mAb in the company’s pipeline will remain in effect and whether the EUA is revised or revoked by the U.S. FDA; changes in expected or existing competition; the company's reliance on third parties; the company's ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, each filed with the Securities and Exchange Commission (SEC), and in the company's other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Media Relations
(781) 208-1747
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
What are the key statistics about COVID-19 impact mentioned in Invivyd's (IVVD) 2024 announcement?
What is the purpose of Invivyd's (IVVD) partnership with Jim Harbaugh?
How is COVID-19 affecting ICU admissions according to Invivyd's (IVVD) announcement?
What population groups are specifically targeted in Invivyd's (IVVD) awareness campaign?
What are the long-term implications of COVID-19 according to Invivyd's (IVVD) announcement?
